INHALE-3 extension study: Inhaled technosphere insulin plus insulin degludec maintains glycemic control
A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...
EurekAlert!13d
Evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...
pharmaphorum2d
Novo Nordisk’s diabetes treatments approved in EU
The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...
EurekAlert!11d
Results of the INHALE-3 extension study: inhaled technosphere insulin plus insulin degludec in T1D
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...